gefitinib has been researched along with Experimental Neoplasms in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (41.38) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, YX; He, YY; Mao, S; Xiao, X; Xie, XX; Xin, MH; Xuan, W; Zhang, S; Zhang, SQ; Zuo, SJ | 1 |
| Abouzid, KAM; Esmat, A; Hossam, M; Ismail, NSM; Lasheen, DS; Mansour, AM; Singab, ANB | 1 |
| Kong, L; Li, Y; Liu, H; Liu, X; Wang, LL; Yuan, F; Zhang, L; Zhang, Y; Zuo, Z | 1 |
| Chen, D; Jiang, S; Li, Z; Liao, C; Liu, Y; Ni, Y; Qiang, L; Qiu, Y; Tu, Z; Wang, D; Yao, Y; Zhang, K; Zhang, W | 1 |
| An, B; Chen, C; Fan, R; Li, J; Li, X; Song, X; Wei, S; Zhang, Q; Zou, Y | 1 |
| Chan, L; Chen, T; He, D; Huang, Y; Yuan, R | 1 |
| Shi, Y; Su, C; Zhao, L; Zheng, Y | 1 |
| Kharbanda, A; Runkle, K; Wang, W; Witze, ES | 1 |
| Brandt, W; Jones, D; Kodama, H; Monette, S; Paluch, LR; Reilly, J; Solomon, SB; Srimathveeravalli, G; Ueshima, E; Vroomen, LG | 1 |
| Ishiguro, H; Ishiguro, Y; Miyamoto, H | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Chen, M; Guo, Y; Huang, J; Jiang, H; Li, M; Xie, Y; Yue, S; Zhang, F; Zhou, G | 1 |
| Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M | 1 |
| Amornphimoltham, P; Chiorini, JA; Gutkind, JS; Schmidt, M; Weller, ML; Wilson, PA | 1 |
| Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL | 1 |
| Fung, AS; Jonkman, J; Tannock, IF | 1 |
| Casanovas, O; Castillo-Ávila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Graupera, M; Hernández-Losa, J; Juliachs, M; Pandiella, A; Piulats, JM; Teixidó, C; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Pepe, S; Raben, D; Tortora, G; Troiani, T; Veneziani, BM | 1 |
| Arribas, J; Baselga, J; Cassia, R; Di Cosimo, S; Guzmán, M; Matar, P; Moreno-Bueno, G; Palacios, J; Rodriguez, S; Rojo, F; Tabernero, J | 1 |
| Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L | 1 |
| Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Fujiwara, M; Ikehara, S; Ikehara, Y; Kodera, Y; Koike, M; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yatabe, Y; Yokoyama, H | 1 |
| Amin, DN; Bielenberg, DR; Heymach, JV; Klagsbrun, M; Lifshits, E | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Cuccato, S; Damiano, V; De Placido, S; Fontanini, G; Tortora, G | 1 |
| Ahmad, T; Anderson, NG; Bundred, NJ; Chan, K; Dobson, R | 1 |
29 other study(ies) available for gefitinib and Experimental Neoplasms
| Article | Year |
|---|---|
Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.
Topics: Amines; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Urea | 2016 |
Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Artemisinins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Nicotinamide Phosphoribosyltransferase; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camphanes; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Screening Assays, Antitumor; Emulsions; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Particle Size; Surface Properties; Vesicular Transport Proteins | 2020 |
Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Female; Gefitinib; Gene Silencing; Humans; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Quinazolines; RNA, Small Interfering; Transfection | 2017 |
Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras.
Topics: Antineoplastic Agents; Apoptosis; Cocarcinogenesis; Cysteine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lipoylation; MCF-7 Cells; Membrane Proteins; Mutation; Neoplasms, Experimental; Proto-Oncogene Proteins p21(ras); Quinazolines | 2017 |
Catheter-based endobronchial electroporation is feasible for the focal treatment of peribronchial tumors.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheterization; Catheters; Cell Death; Cisplatin; Computer Simulation; Electrochemotherapy; Feasibility Studies; Gefitinib; Humans; Lung Neoplasms; Male; Models, Biological; Neoplasms, Experimental; Sus scrofa; Time Factors; Tomography, X-Ray Computed | 2018 |
Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia.
Topics: Antibodies, Neutralizing; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Lung Diseases, Interstitial; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tyrphostins; Up-Regulation | 2013 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation; Gene Silencing; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden | 2009 |
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.
Topics: Animals; Cell Line, Tumor; Dependovirus; ErbB Receptors; Female; Gefitinib; Gene Expression; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Isoantigens; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptors, Virus; Transduction, Genetic; Tyrphostins | 2010 |
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Embryonal; Cell Survival; Cetuximab; Choriocarcinoma; Endodermal Sinus Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Lapatinib; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptor, ErbB-3; Teratocarcinoma; Testicular Neoplasms; Transplantation, Heterologous | 2013 |
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous | 2013 |
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Blotting, Western; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation, Ionizing; Survival Rate; Tumor Cells, Cultured | 2002 |
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2004 |
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2006 |
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Synergism; Endothelial Growth Factors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Growth Substances; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
Topics: Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2001 |